Efficacy and Safety of Ablative Fractional Laser-Assisted Delivery of Methotrexate in Adults with Localized Scleroderma: A Randomized and Controlled Clinical Trial

Localized scleroderma (LS) is an autoimmune disease with sclerosis of the skin as the main manifestation. Currently, there is no specific treatment for LS. The effectiveness of ablative fractional laser (AFL) therapy for LS has been demonstrated in several studies. Combining ablative fractional Er:Y...

Full description

Saved in:
Bibliographic Details
Main Authors: Qing Guo (Author), Mingjie He (Author), Junjie Cen (Author), Danqi Huang (Author), Shaoyun Hao (Author), Zengqi Tang (Author), Hui Xiong (Author)
Format: Book
Published: MDPI AG, 2022-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ff7bd523868b44c7bc3337acfa7a8d7f
042 |a dc 
100 1 0 |a Qing Guo  |e author 
700 1 0 |a Mingjie He  |e author 
700 1 0 |a Junjie Cen  |e author 
700 1 0 |a Danqi Huang  |e author 
700 1 0 |a Shaoyun Hao  |e author 
700 1 0 |a Zengqi Tang  |e author 
700 1 0 |a Hui Xiong  |e author 
245 0 0 |a Efficacy and Safety of Ablative Fractional Laser-Assisted Delivery of Methotrexate in Adults with Localized Scleroderma: A Randomized and Controlled Clinical Trial 
260 |b MDPI AG,   |c 2022-10-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics14112261 
500 |a 1999-4923 
520 |a Localized scleroderma (LS) is an autoimmune disease with sclerosis of the skin as the main manifestation. Currently, there is no specific treatment for LS. The effectiveness of ablative fractional laser (AFL) therapy for LS has been demonstrated in several studies. Combining ablative fractional Er:YAG laser therapy with topical methotrexate may yield therapeutic benefits for patients with LS. To compare the efficacy and safety of AFL-assisted delivery of methotrexate in adults with LS, we randomly divided patients into an AFL therapy group and an ablative fractional laser-assisted delivery of methotrexate (AFL+MTX) therapy group. Laser and assisted drug delivery treatment were given every four weeks for four months, and 22 patients completed the trial. Ultrasound measurements of dermal thickness and histological fibrosis degree and the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) score were used to assess therapeutic effects. Treatment results showed that both AFL and AFL-assisted methotrexate delivery were effective in treating LS, and the laser combined with methotrexate therapy was more effective in improving clinical appearance (<i>p</i> value = 0.042) and dermal thickness (<i>p</i> value = 0.016). No serious adverse reaction occurred in either group. In conclusion, AFL and assisted delivery of methotrexate are effective and safe treatments for LS. 
546 |a EN 
690 |a ablative fractional laser 
690 |a methotrexate 
690 |a laser-assisted drug delivery 
690 |a localized scleroderma 
690 |a morphea 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 14, Iss 11, p 2261 (2022) 
787 0 |n https://www.mdpi.com/1999-4923/14/11/2261 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/ff7bd523868b44c7bc3337acfa7a8d7f  |z Connect to this object online.